These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18081733)

  • 1. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.
    McHutchison JG; Patel K; Schiff ER; Gitlin N; Mur RE; Everson GT; Carithers RL; Davis GL; Marcellin P; Shiffman ML; Harvey J; Albrecht JK;
    Aliment Pharmacol Ther; 2008 Mar; 27(5):422-32. PubMed ID: 18081733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
    Rolachon A; Kézachian G; Causse X; Baud M; Leroy V; Maynard-Muet M; Pasquier D; Zarski JP
    Gastroenterol Clin Biol; 1997; 21(12):924-8. PubMed ID: 9587555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.
    Neuman MG; Benhamou JP; Bourliere M; Ibrahim A; Malkiewicz I; Asselah T; Martinot-Peignoux M; Shear NH; Katz GG; Akremi R; Benali S; Boyer N; Lecomte L; Le Breton V; Le Guludec G; Marcellin P
    Cytokine; 2002 Jan; 17(2):108-17. PubMed ID: 11886178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
    Lau DT; Kleiner DE; Ghany MG; Park Y; Schmid P; Hoofnagle JH
    Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
    Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.